Frevecitinib

Phase 2

KKinaset Therapeutics Inc

Frevecitinib is one of 2 therapeutic programs targeting Severe Asthma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Severe AsthmaRecruiting

Severe AsthmaPhase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Severe Asthma

#DrugCompanyPhaseTrials

Tezspire

AstraZeneca

Phase 3

3 2

Frevecitinib

KKinaset Therapeutics Inc

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Severe Asthma

NCT07532265

Clinical

Trials by Indication[1]

Severe Asthma1 trial

A Phase 2 Randomized Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Three Doses of Frevecitinib (KN-002) in Patients With Severe Asthma

Recruiting·KKinaset Therapeutics Inc·Phase 2·NCT07532265·512 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Frevecitinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Frevecitinib. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Kinaset Therapeutics Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: KKinaset Therapeutics Inc

Frevecitinib

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Severe Asthma1 trial

References

Drug Info

Quick Facts

Related News